Cargando…

Increasing human monoclonal antibody cloning efficiency with a whole-cell modified immunoglobulin-capture assay (mICA)

Expression cloning of fully human monoclonal antibodies (hmAbs) is seeing powerful utility in the field of vaccinology, especially for elucidating vaccine-induced B-cell responses and novel vaccine candidate antigen discovery. Precision of the hmAb cloning process relies on efficient isolation of hm...

Descripción completa

Detalles Bibliográficos
Autores principales: Siris, Sara, Gladstone, Camilla A., Guo, Yanping, Patel, Radhika, Pinder, Christopher L., Shattock, Robin J., McKay, Paul F., Langford, Paul R., Bidmos, Fadil A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272928/
https://www.ncbi.nlm.nih.gov/pubmed/37334357
http://dx.doi.org/10.3389/fimmu.2023.1184510
_version_ 1785059605160656896
author Siris, Sara
Gladstone, Camilla A.
Guo, Yanping
Patel, Radhika
Pinder, Christopher L.
Shattock, Robin J.
McKay, Paul F.
Langford, Paul R.
Bidmos, Fadil A.
author_facet Siris, Sara
Gladstone, Camilla A.
Guo, Yanping
Patel, Radhika
Pinder, Christopher L.
Shattock, Robin J.
McKay, Paul F.
Langford, Paul R.
Bidmos, Fadil A.
author_sort Siris, Sara
collection PubMed
description Expression cloning of fully human monoclonal antibodies (hmAbs) is seeing powerful utility in the field of vaccinology, especially for elucidating vaccine-induced B-cell responses and novel vaccine candidate antigen discovery. Precision of the hmAb cloning process relies on efficient isolation of hmAb-producing plasmablasts of interest. Previously, a novel immunoglobulin-capture assay (ICA) was developed, using single protein vaccine antigens, to enhance the pathogen-specific hmAb cloning output. Here, we report a novel modification of this single-antigen ICA using formalin-treated, fluorescently stained whole cell suspensions of the human bacterial invasive pathogens, Streptococcus pneumoniae and Neisseria meningitidis. Sequestration of IgG secreted by individual vaccine antigen-specific plasmablasts was achieved by the formation of an anti-CD45-streptavidin and biotin anti-IgG scaffold. Suspensions containing heterologous pneumococcal and meningococcal strains were then used to enrich for polysaccharide- and protein antigen-specific plasmablasts, respectively, during single cell sorting. Following application of the modified whole-cell ICA (mICA), ~61% (19/31) of anti-pneumococcal polysaccharide hmAbs were cloned compared to 14% (8/59) obtained using standard (non-mICA) methods – representing a ~4.4-fold increase in hmAb cloning precision. A more modest ~1.7-fold difference was obtained for anti-meningococcal vaccine hmAb cloning; ~88% of hmAbs cloned via mICA versus ~53% cloned via the standard method were specific for a meningococcal surface protein. VDJ sequencing revealed that cloned hmAbs reflected an anamnestic response to both pneumococcal and meningococcal vaccines; diversification within hmAb clones occurred by positive selection for replacement mutations. Thus, we have shown successful utilization of whole bacterial cells in the ICA protocol enabling isolation of hmAbs targeting multiple disparate epitopes, thereby increasing the power of approaches such as reverse vaccinology 2.0 (RV 2.0) for bacterial vaccine antigen discovery.
format Online
Article
Text
id pubmed-10272928
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102729282023-06-17 Increasing human monoclonal antibody cloning efficiency with a whole-cell modified immunoglobulin-capture assay (mICA) Siris, Sara Gladstone, Camilla A. Guo, Yanping Patel, Radhika Pinder, Christopher L. Shattock, Robin J. McKay, Paul F. Langford, Paul R. Bidmos, Fadil A. Front Immunol Immunology Expression cloning of fully human monoclonal antibodies (hmAbs) is seeing powerful utility in the field of vaccinology, especially for elucidating vaccine-induced B-cell responses and novel vaccine candidate antigen discovery. Precision of the hmAb cloning process relies on efficient isolation of hmAb-producing plasmablasts of interest. Previously, a novel immunoglobulin-capture assay (ICA) was developed, using single protein vaccine antigens, to enhance the pathogen-specific hmAb cloning output. Here, we report a novel modification of this single-antigen ICA using formalin-treated, fluorescently stained whole cell suspensions of the human bacterial invasive pathogens, Streptococcus pneumoniae and Neisseria meningitidis. Sequestration of IgG secreted by individual vaccine antigen-specific plasmablasts was achieved by the formation of an anti-CD45-streptavidin and biotin anti-IgG scaffold. Suspensions containing heterologous pneumococcal and meningococcal strains were then used to enrich for polysaccharide- and protein antigen-specific plasmablasts, respectively, during single cell sorting. Following application of the modified whole-cell ICA (mICA), ~61% (19/31) of anti-pneumococcal polysaccharide hmAbs were cloned compared to 14% (8/59) obtained using standard (non-mICA) methods – representing a ~4.4-fold increase in hmAb cloning precision. A more modest ~1.7-fold difference was obtained for anti-meningococcal vaccine hmAb cloning; ~88% of hmAbs cloned via mICA versus ~53% cloned via the standard method were specific for a meningococcal surface protein. VDJ sequencing revealed that cloned hmAbs reflected an anamnestic response to both pneumococcal and meningococcal vaccines; diversification within hmAb clones occurred by positive selection for replacement mutations. Thus, we have shown successful utilization of whole bacterial cells in the ICA protocol enabling isolation of hmAbs targeting multiple disparate epitopes, thereby increasing the power of approaches such as reverse vaccinology 2.0 (RV 2.0) for bacterial vaccine antigen discovery. Frontiers Media S.A. 2023-06-02 /pmc/articles/PMC10272928/ /pubmed/37334357 http://dx.doi.org/10.3389/fimmu.2023.1184510 Text en Copyright © 2023 Siris, Gladstone, Guo, Patel, Pinder, Shattock, McKay, Langford and Bidmos https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Siris, Sara
Gladstone, Camilla A.
Guo, Yanping
Patel, Radhika
Pinder, Christopher L.
Shattock, Robin J.
McKay, Paul F.
Langford, Paul R.
Bidmos, Fadil A.
Increasing human monoclonal antibody cloning efficiency with a whole-cell modified immunoglobulin-capture assay (mICA)
title Increasing human monoclonal antibody cloning efficiency with a whole-cell modified immunoglobulin-capture assay (mICA)
title_full Increasing human monoclonal antibody cloning efficiency with a whole-cell modified immunoglobulin-capture assay (mICA)
title_fullStr Increasing human monoclonal antibody cloning efficiency with a whole-cell modified immunoglobulin-capture assay (mICA)
title_full_unstemmed Increasing human monoclonal antibody cloning efficiency with a whole-cell modified immunoglobulin-capture assay (mICA)
title_short Increasing human monoclonal antibody cloning efficiency with a whole-cell modified immunoglobulin-capture assay (mICA)
title_sort increasing human monoclonal antibody cloning efficiency with a whole-cell modified immunoglobulin-capture assay (mica)
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272928/
https://www.ncbi.nlm.nih.gov/pubmed/37334357
http://dx.doi.org/10.3389/fimmu.2023.1184510
work_keys_str_mv AT sirissara increasinghumanmonoclonalantibodycloningefficiencywithawholecellmodifiedimmunoglobulincaptureassaymica
AT gladstonecamillaa increasinghumanmonoclonalantibodycloningefficiencywithawholecellmodifiedimmunoglobulincaptureassaymica
AT guoyanping increasinghumanmonoclonalantibodycloningefficiencywithawholecellmodifiedimmunoglobulincaptureassaymica
AT patelradhika increasinghumanmonoclonalantibodycloningefficiencywithawholecellmodifiedimmunoglobulincaptureassaymica
AT pinderchristopherl increasinghumanmonoclonalantibodycloningefficiencywithawholecellmodifiedimmunoglobulincaptureassaymica
AT shattockrobinj increasinghumanmonoclonalantibodycloningefficiencywithawholecellmodifiedimmunoglobulincaptureassaymica
AT mckaypaulf increasinghumanmonoclonalantibodycloningefficiencywithawholecellmodifiedimmunoglobulincaptureassaymica
AT langfordpaulr increasinghumanmonoclonalantibodycloningefficiencywithawholecellmodifiedimmunoglobulincaptureassaymica
AT bidmosfadila increasinghumanmonoclonalantibodycloningefficiencywithawholecellmodifiedimmunoglobulincaptureassaymica